Deal Watch: Roche/Foundation Medicine Highlights Hyper Deal-Making During J.P. Morgan
Biogen will purchase GSK spinout Convergence to bolster its pain portfolio, while Tekmira and OnCore are merging to create a new company focused on hepatitis B. Two J&J units struck deals during the week in Alzheimer’s and gastrointestinal indications, as Lilly teamed up with Merck and Bristol for combo trials to keep its drugs relevant in the PD-1 world.
You may also be interested in...
Microbiome-based research is gaining credibility as a means to discover novel therapeutics. Now big pharmas like J&J and Pfizer are evaluating partnering opportunities in the burgeoning field – with potential therapies starting to enter the clinic – as they look to strike the appropriate balance between internal and external research.
With an emphasis on early disease intervention, J&J’s Janssen R&D unit launched three new research platforms – disease prevention, disease interception and the microbiome.
With proof of high response rates in small studies of B-cell malignancies in the rear view, sponsors focus on the next hurdles – launching potentially registrational studies in 2015, honing plans for a smooth-running manufacturing process and branching out into new indications.